Dental implant procedures require that patients have sufficient alveolar bone mass to endure the transplant of an artificial tooth root. While ArBlast’s “injection-type cultured bone” is effective in patients suffering loss of bone mass, some individuals are predisposed to alveolar bone mass loss that advances much more quickly than alveolar bone is regenerated.
For such individuals, it is a waste of time and money to undergo bone regeneration and dental implant procedures, because it is impossible in such patients to achieve stable and long-lasting artificial tooth root transplantation.

On the basis of our invention, for which we have filed a patent application, we are developing a technology to examine a patient’s genes to assess the extent of his/her bone absorption and, on the basis of the assessment results, judge whether dental implant surgery is applicable to the patient.